OmniAb (OABI)

The company’s core offering is built around engineered transgenic animal systems and screening capabilities designed to produce broad antibody repertoires against disease targets. OmniAb describes this integrated approach as “Biological Intelligence,” reflecting the way its technologies harness immune systems to create antibody candidates with characteristics suitable for human therapeutics. The platform includes multiple species and formats, giving partners flexibility in the type of antibody response they want to explore.

OmniAb’s business model is typical of enabling biotechnology companies: it seeks value through technology access arrangements, research collaboration economics, milestone payments, and potential royalties if partner-discovered therapies succeed. This makes the company’s long-term performance closely tied to the breadth of its partner base and the progress of programs that originate from its discovery engine.

For investors, OmniAb represents exposure to the growing antibody therapeutics market without relying solely on a single drug candidate. Its distinguishing feature is the combination of proprietary biological systems and discovery know-how that can be applied across many disease areas by external drug developers.